Latest News
Web Date: March 21, 2016

Merck, Harvard sign hefty drug pact

Cancer compounds from chemist Matthew Shair’s lab bring in $20 million
Department: Business
Keywords: pharmaceuticals, biotech, start-ups

In the largest license fee ever for a technology developed at Harvard University, Merck & Co. will pay $20 million up front for preclinical compounds for leukemia developed in the labs of chemist Matthew Shair.

Merck gains small molecules that block enzymes that control the transcription of gene expression that goes awry in acute myeloid leukemia (AML). The compounds are the culmination of several years of research in Shair’s lab, which works at the intersection . . .

To view the rest of this content, please log in with your ACS ID.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society